晚期胃癌患者化疗中胸腺肽α1治疗疗效的临床研究

目的：探讨应用流式细胞仪（FCM）检测胃癌患者外周血免疫指标,以评价胸腺肽α1联合化疗对胃癌患者免疫功能的影响。方法：70例胃癌患者随机分为用药组和对照组。用药组35例采用胸腺肽α1＋化疗,对照组35例单用化疗,两组化疗方案相同。胸腺肽α1每次1.6mg,每周2次,连续4周（共8针）。28天为一疗程,共用2个疗程。采用FCM检测两组患者化疗前后外周血CD4、CD8、CD3＋CD4＋、CD3＋CD8＋免疫指标。结果：用药组CD4、CD8、CD3＋CD4＋、CD4/CD8均高于化疗前和对照组化疗后水平,均具有统计学意义（P〈0.05）。结论：胸腺肽α1配合化疗能提高患者的免疫功能,用FCM检测外周血免疫指标为临床观察肿瘤患者的免疫状态提供有效的依据。     

非霍奇金淋巴瘤患者外周血中CD4＋CD25＋调节性T细胞亚群变化初探

目的：检测非霍奇金淋巴瘤（non—Hodgkin’s lymphoma,NHL）患者外周血中CD4＋CD25＋调节性T细胞（CD4＋CD25＋regulatoryTcell,Treg）的改变,探讨Treg与NHL的相关性。方法：病例组（n=60）为本院收治的初诊NHL患者,对照组（n=60）为本院健康体检者,用流式细胞技术联合标记CD4、CD25检测对照组及病例组化疗前、化疗后的外周血中CD4＋CD25＋调节性T细胞的分布特点。结果：（1）病例组化疗前外周血中CD4＋细胞比例显著低于对照组（P〈0．05）,CD4＋CD25＋调节性T细胞比例显著高于对照组（P〈0．05）;（2）病例组化疗后,CD4＋细胞比例明显高于化疗前（P〈0．05）,CD4＋CD25＋调节性T细胞比例明显低于化疗前（P〈0．05）;（3）病例组化疗后CD4＋细胞比例与对照组无显著差异（P〉0．05）,而CD4＋CD25＋调节性T细胞比例显著高于对照组（P〈0．05）。结论：非霍奇金淋巴瘤患者外周血中CD4＋CD25＋调节性T细胞比例升高,存在机体免疫抑制,化疗可降低CD4＋CD25＋调节性T细胞比例。     

慢性阻塞性肺疾病患者外周血CD4~＋CD25~＋CD127~（（Low/-））调节性T细胞的检测及临床意义

目的：研究CD4＋CD25＋CD127（Low/-）调节性T细胞在慢性阻塞性肺疾病（COPD）急性发作期外周血中的比例改变及其临床意义。方法：以25例COPD急性发作期患者外周血为研究组,20名正常人外周血作为对照组,采用三色直接荧光素标记法和多参数流式细胞仪检测外周血CD4＋CD25＋CD127（Low/-）调节性T细胞的比例,同时检测外周血C-反应蛋白（CRP）、血沉（ESR）、免疫球蛋白（Ig）等水平。结果：COPD急性发作期患者外周血CD4＋CD25＋CD127（Low/-）调节性T细胞占外周血CD4＋T淋巴细胞的比例明显低于健康对照组（P〈0.01）。而COPD急性发作期患者外周血CRP、ESR、Ig等水平明显高于健康对照组（P〈0.05）。COPD患者外周血调节T细胞下降与CRP和IgG升高成负相关。结论：COPD患者外周血CD4＋CD25＋CD127（Low/-）调节性T细胞在CD4＋T淋巴细胞的比例明显减少,调节性T细胞等免疫调节因素可能在COPD的发病机制发挥重要作用。     

基于物理过滤与原位杂交技术的骨肉瘤循环肿瘤细胞检测及临床意义

目的:探寻一种有效地从骨肉瘤患者外周血中富集并鉴定循环肿瘤细胞的方法。方法:利用基于物理过滤与原位杂交结合的技术对骨肉瘤患者外周血循环肿瘤细胞分离并鉴定。采用直径8μm纳米滤膜截留外周血中体积较大的白细胞及肿瘤细胞,利用多重RNA原位杂交技术检测CD45、EpCAM、CK8、CK18、CK19、vimentin及twist基因表达,并根据结果对滤膜截留下的细胞进行鉴定并分型。结果:本研究所使用的基于物理过滤与原位杂交技术的循环肿瘤细胞检测方法可以高效地从骨肉瘤患者外周血中富集骨肉瘤循环肿瘤细胞,该方法富集细胞的效率超过90%。15例健康志愿者中1例志愿者检测结果阳性。20例纳入研究的骨肉瘤患者中19例患者外周血中检测出CTC,CTC计数范围为0-20。肿瘤转移患者外周血CTC计数为11.33±5.88,肿瘤未转移患者外周血CTC计数为4.36±2.98,差异具有统计学意义(P=0.0022)。肿瘤转移患者外周血间质型CTC比例高于肿瘤未转移患者(P=0.0031)。结论:利用基于物理过滤与原位杂交结合的技术可以有效地检测骨肉瘤患者外周血循环肿瘤细胞。CTC检测结果可以作为辅助判断肿瘤转移情况的辅助指标。     

滤泡辅助性T细胞在特发性血小板减少性紫癜患者的变化及其意义

目的：研究滤泡辅助性T细胞（T follicular helper cells,Tfh）在免疫性血小板减少性紫癜（immune thrombocytopenic purpura,ITP）患者的表达并探讨其临床意义。方法：用流式细胞术检测20例健康人、25例ITP患者外周血CXCR5＋CD4＋T细胞占CD4＋T细胞的比例。结果：与健康对照组相比,ITP患者外周血CXCR5＋CD4＋T细胞占CD4＋T细胞的比例显著增高（P〈0.05）。结论：Tfh在ITP患者外周血比例增高,为Tfh能否为ITP的免疫调节和干预提出新的方向提供了证据。     

哮喘患者诱导痰和外周血CD3~＋CD56~＋NKT细胞的检测及意义

目的：研究CD3＋CD56＋NKT细胞在哮喘患者急性发作期诱导痰和外周血中的比例改变,并探讨其临床意义。方法：以28例哮喘急性发作期患者为研究组,22名正常人作为对照组,采用二色直接荧光素标记法和多参数流式细胞仪检测诱导痰和外周血CD3＋CD56＋NKT细胞的比例,同时检测外周血IL-4、Ig-E及INF-γ等水平。结果：哮喘患者急性发作期诱导痰和外周血CD3＋CD56＋NKT细胞明显高于健康对照组（P〈0.01）。哮喘患者急性发作期外周血IL-4、Ig-E及INF-γ等水平明显高于健康对照组（P〈0.05）。哮喘患者外周血中CD3＋CD56＋NKT细胞比例与IL-4、Ig-E及INF-γ升高成正相关。结论：哮喘患者急性发作期诱导痰和外周血中的CD3＋CD56＋NKT细胞明显增高,CD3＋CD56＋NKT细胞可能通过调节IL-4、Ig-E及INF-γ等细胞因子从而在哮喘的发病机制发挥重要作用。     

用流式细胞术评价一种新型人工肝材料的生物相容性

目的通过用流式细胞术（FCM）观察丙稀酰胺接枝改性聚丙烯膜 （PP-g-AAm）的生物相容性,来评价FCM在检测医用生物材料的生物相容性中的作用.方法：用材料浸提液培养L929细胞24 h后用FCM检测细胞增殖周期; 用改性前、后的膜材料分别与新提取的PRP（富含血小板血浆）和PBMC（末梢血单个核细胞）孵育培养后,用FCM分别检测血小板和PBMC的激活标志物CD62P、CD63和CD69.结果：PP-g-AAm 组的PI与阴性组及空白对照组比较差异无统计学意义（P=0.063,P=0.053）,而与阳性对照组比较差异有统计学意义（P=0.002）.PP-g-AAm膜组CD62P、CD63及CD69的表达率明显少于对照组（P=0.042, P=0.004,P=0.013）.结论：PP-g-AAm无细胞毒性并具有良好的生物相容性,FCM在生物材料的生物相容性评价中有着广泛的应用价值.     

青藤碱对人外周血CD4^＋T淋巴细胞增殖和细胞内Ca^2＋浓度影响的体外研究

目的探讨青藤碱（SIN）对人外周血CD4^＋T淋巴细胞增殖和细胞内Ca^2＋浓度的体外影响及其效应机制。方法建立体外人外周血CD4^＋T淋巴细胞模型,分别作以下处理：（1）空白对照组;（2）环孢素（CsA）组（50ng／m1）;（3）低浓度SIN组（10μmol／1）;（4）中浓度SIN组（200μmol／1）;（5）高浓度SIN组（1000μmol／1）。分别用MTT比色法和流式细胞术（FCM）检测CD4^＋细胞增殖和细胞内Ca^2＋荧光强度。采用方差分析比较各组间差异的统计学意义。结果（1）高浓度SIN组、中浓度SIN组与其他各组细胞增殖抑制率存在差异（F=1444．228,P=0．000）;（2）FCM检测细胞内Ca^2＋浓度结果：中浓度SIN组、高浓度SIN组与其他各组差异有统计学意义（F=479．055,P=0．000）;（3）经SIN处理后,人外周血CD4^＋T淋巴细胞增殖抑制率和细胞内Ca^2＋浓度之间存在负相关r=-0．836,P=0．005）。结论SIN能浓度依赖性地抑制人外周血CD4^＋T淋巴细胞增殖和细胞内Ca^2＋浓度升高,人外周血CD4^＋T淋巴细胞增殖抑制率和细胞内Ca^2＋浓度之间存在显著性负相关。     

SLE患者PBMC凋亡状态及相关基因表达的研究

探讨外周血单个核细胞(PBMC)凋亡及其基因调控在系统性红斑狼疮(systemic lupus erythematosus,SLE)发病机制中的作用.用流式细胞仪(FCM)检测PBMC凋亡百分率及T细胞亚群的凋亡状态;用RT-PCR检测PBMC bcl-2和bax的mRNA表达;用FCM检测凋亡相关基因bcl-2,bax,fas,p53和c-myc的蛋白表达.结果显示,SLE患者PBMC凋亡百分率明显高于正常人,且活动期患者高于非活动期患者.SLE活动期患者CD4+,CD8+T细胞数明显低于正常人;非活动期患者CD8+T细胞数明显低于正常人,而CD4+T细胞数与正常人比较无统计学差异;SLE患者PBMC bcl-2和bax mRNA表达与正常人比较无统计学差异;SLE患者PBMC bcl-2,bax和fas蛋白表达明显高于正常人,p53和c-myc蛋白表达在各组之间无统计学差异.SLE患者PBMC凋亡百分率增高、外周血T细胞亚群的异常及bcl-2,bax和fas蛋白表达增高,在SLE发病机制中可能起了一定的作用.     

不同RF型类风湿性关节炎患者Th17相关细胞因子表达研究

目的：探讨类风湿因子阳性与阴性类风湿关节炎（rheumatoid arthritis,RA）患者外周血中辅助T细胞（Th17）及相关细胞因子白介素17（interleukin,IL-17）,白介素6（interleukin,IL-6）表达的差异。方法：收集RA患者51例,根据RF测定分为RF＋、RF-组,健康查体者（对照组）20例,采用流式细胞术检测受检者外周血单个核细胞（PBMC）的Th17细胞的百分率;以酶联免疫吸附法（ELISA）检测受检者血浆中IL-17,IL-6的水平。结果：RA患者CD4＋IL-17＋T细胞,IL-17、IL-6水平均高于对照组,RF因子阳性与阴性RA患者之间CD4＋IL-17＋T细胞,IL-17、IL-6表达水平均存在差异有统计学意义。结论：在RA中不同RF型免疫反应和炎症表达的不同,可能与Th17及相关细胞因子表达差异有关。     

肿瘤干细胞与胃癌

最近的一项研究报导,采用流式细胞仪分选技术从人胃癌细胞株中分离出CD44^＋胃癌干细胞. 20～30×10³个CD44＋细胞入NOD/SCID 鼠腹部皮下和胃浆膜下能形成胃癌移植瘤, 100×10³个CD44^－的细胞入NOD/SCID 鼠体内不形成肿瘤.采用无血清、无粘附间质的干细胞体外培养方法,发现CD44^＋的细胞能形成肿瘤微球体,具有自我更新能力,而CD44^－的细胞则不形成球形克隆.上述的实验结果说明,在人胃癌细胞株中存在胃癌肿瘤干细胞.据此可以相信,胃癌干细胞是胃癌细胞中具有自我更新及分化潜能的一小群细胞,不能被目前的化疗、放疗等抗癌治疗措施所杀灭,是胃癌术后复发、肿瘤进展扩散转移的根源.胃癌干细胞可能来源于骨髓干细胞.随着对胃癌肿瘤干细胞生物学研究的深入,必将为胃癌的临床诊断和治疗提供新的策略.     

肿瘤干细胞及肝癌肿瘤干细胞

肿瘤干细胞理论认为只有存在于肿瘤中的少量干细胞性质的细胞群体对肿瘤发生和发展起着决定作用,肿瘤是由干细胞突变积累而形成的无限增殖的异常组织,这一理论的提出使人们对肿瘤发生机制的认识上升到了一个新的高度,也引起了研究者的广泛关注;肝癌是我国常见的恶性肿瘤之一,我国肝癌死亡率居世界之首,目前对肝癌的研究是我国恶性肿瘤防治的重点工作,现对当前肿瘤干细胞与肝癌肿瘤干细胞相关方面的最新研究进展作一概述。     

Stem-like Cancer Cells Are Inducible by Increasing Genomic Instability in Cancer Cells

The existence of cancer stem cells (CSCs) or stem-like cancer cells (SLCCs) is regarded as the cause of tumor formation and recurrence. However, the origin of such cells remains controversial with two competing hypotheses: CSCs are either transformed from tissue adult stem cells or dedifferentiated from transformed progenitor cells. Compelling evidence has determined the chromosomal aneuploidy to be one of the hallmarks of cancer cells, indicating genome instability plays an important role in tumorigenesis, for which CSCs are believed to be the initiator. To gain direct evidence that genomic instability is involved in the induction of SLCCs, we utilized multiple approaches to enhance genomic instability and monitored the percentage of SLCC in cultured cancer cells. Using side population (SP) cells as a marker for SLCC in human nasopharyngeal carcinoma (NPC) and CD133 for human neuroblastoma cells, we found that DNA damage inducers, UV and mitomycin C were capable of increasing SP cells in NPC CNE-2 and neuroblastoma SKN-SH cells. Likewise, either overexpression of a key regulator of cell cycle, Mad2, or knock down of Aurora B, an important kinase in mitosis, or Cdh1, a key E3 ligase in cell cycle, resulted in a significant increase of SP cells in CNE-2. More interestingly, enrichment of SP cells was observed in recurrent tumor tissues as compared with the primary tumor in the same NPC patients. Our study thus suggested that, beside transformation of tissue stem cells leading to CSC generation, genomic instability could be another potential mechanism resulting in SLCC formation, especially at tumor recurrence stage.     

肿瘤干细胞与卵巢癌研究进展

近年来,肿瘤干细胞学说作为肿瘤发生发展的重要原因获得越来越多的认可。肿瘤干细胞是指肿瘤中存在的含量极少、具有无限增殖潜能的干细胞样肿瘤细胞,它们能自我更新、分化、迁徙,是导致肿瘤发生、发展、转移和耐药的重要原因。卵巢癌也可能是卵巢癌干细胞所致的疾病。卵巢癌干细胞的分离鉴定正处于起始阶段,针对卵巢癌干细胞的靶向治疗可能在卵巢癌治疗中具有重要作用,为临床彻底治愈卵巢癌带来希望。     

癌、干细胞和癌干细胞共同拥有的信号传导通路

干细胞（SC）是具有无限自我更新和分化能力的细胞,随着对SC研究的不断深入,人们发现SC与肿瘤细胞有许多共性,如无限增生能力、迁移能力及在某些条件下能相互转化,故提出了肿瘤起源于SC的学说。探讨癌、SC和癌干细胞（CSC）之间可能存在的共同信号传导通路,以便发现治疗CSC的靶位。     

Durotaxis by Human Cancer Cells

Durotaxis is a type of directed cell migration in which cells respond to a gradient of extracellular stiffness. Using automated tracking of positional data for large sample sizes of single migrating cells, we investigated 1) whether cancer cells can undergo durotaxis; 2) whether cell durotactic efficiency varies depending on the regional compliance of stiffness gradients; 3) whether a specific cell migration parameter such as speed or time of migration correlates with durotaxis; and 4) whether Arp2/3, previously implicated in leading edge dynamics and migration, contributes to cancer cell durotaxis. Although durotaxis has been characterized primarily in nonmalignant mesenchymal cells, little is known about its role in cancer cell migration. Diffusible factors are known to affect cancer cell migration and metastasis. However, because many tumor microenvironments gradually stiffen, we hypothesized that durotaxis might also govern migration of cancer cells. We evaluated the durotactic potential of multiple cancer cell lines by employing substrate stiffness gradients mirroring the physiological stiffness encountered by cells in a variety of tissues. Automated cell tracking permitted rapid acquisition of positional data and robust statistical analyses for migrating cells. These durotaxis assays demonstrated that all cancer cell lines tested (two glioblastoma, metastatic breast cancer, and fibrosarcoma) migrated directionally in response to changes in extracellular stiffness. Unexpectedly, all cancer cell lines tested, as well as noninvasive human fibroblasts, displayed the strongest durotactic migratory response when migrating on the softest regions of stiffness gradients (2–7 kPa), with decreased responsiveness on stiff regions of gradients. Focusing on glioblastoma cells, durotactic forward migration index and displacement rates were relatively stable over time. Correlation analyses showed the expected correlation with displacement along the gradient but much less with persistence and none with cell speed. Finally, we found that inhibition of Arp2/3, an actin-nucleating protein necessary for lamellipodial protrusion, impaired durotactic migration.     

PuraMatrix Encapsulation of Cancer Cells

Increasing evidence suggests that culturing cancer cells in three dimensions more accurately recapitulates the complexity of tumor biology. Many of these models utilize reconstituted basement membrane derived from animals which contain a variable amount of growth factors and cytokines that can influence the growth of these cell culture models. Here, we describe in detail the preparation and use of PuraMatrix, a commercially available self assembling peptide gel that is devoid of animal-derived material and pathogens to encapsulate and propagate the ovarian cancer cell line, OVCAR-5. We begin by describing how to prepare the PuraMatrix prior to use. Next, we demonstrate how to properly mix the PuraMatrix and cell suspension to encapsulate the cells in the hydrogel. Upon the addition of cell culture media or injection into a physiological environment, the peptide component of PuraMatrix rapidly self assembles into a 3D hydrogel that exhibits a nanometer scale fibrous structure with an average pore size of 5-200 nm¹. In addition, we demonstrate how to propagate cultures grown in encapsulated PuraMatrix. When encapsulated in PuraMatrix, OVCAR-5 cells assemble into three dimensional acinar structures that more closely resemble the morphology of micrometastatic nodules observed in the clinic than monolayer in vitro models. Using confocal microscopy we illustrate the appearance of representative OVCAR-5 cells encapsulated in PuraMatrix on day 1, 3, 5, and 7 post plating. The use of PuraMatrix to culture cancer cells should improve our understanding of the disease and allow us to assess treatment response in more clinically predictive model systems.Download video file.^{(85M, mp4)}